All In Biotech

Drug Trial Radar · NCT04027309

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)

Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 777 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

777

Actual

Start

Dec 20, 2019

Primary completion

Oct 2025

Study completion Jun 2033

Sponsor

Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG); Astellas Pharma Global Development, Inc.
First posted
Jul 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML). Addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy prolongs event-free survival (EFS) and overall survival (OS) in patients with a FLT3 mutation. Gilteritinib is a more potent and more specific inhibitor of mutant FLT3 in comparison to midostaurin and has shown promising clinical activity in AML.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-2

Interventions

  • GilteritinibDrug

    Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin

  • MidostaurinDrug

    Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overal survival (OS)Time frame: Approximately up to 70 months following first patient enrolment

Locations

193 sites in 13 countries. Site status is shown where the registry gives one.

  • AU-Adelaide-FLINDERS

    Adelaide, Australia

  • AU-Adelaide-RAH

    Adelaide, Australia

  • AU-Brisbane-PAH

    Brisbane, Australia

  • AU-Brisbane-RBWH

    Brisbane, Australia

  • AU-Camperdown-RPA

    Camperdown, Australia

  • AU-Douglas-TOWNSVILLE

    Douglas, Australia

  • AU-Geelong VIC-BARWONHEALTH

    Geelong, Australia

  • AU-Gosford NSW-GOSFORDHOSPITAL

    Gosford, Australia

  • AU-Hobart TAS-RHOBART

    Hobart, Australia

  • AU-Melbourne-ALFRED

    Melbourne, Australia

  • AU-Melbourne-AUSTIN

    Melbourne, Australia

  • AU-Melbourne-BOXHILL

    Melbourne, Australia

  • AU-Melbourne-MONASH

    Melbourne, Australia

  • AU-Melbourne-RMELBOURNE

    Melbourne, Australia

  • AU-Melbourne-SVHM

    Melbourne, Australia

  • AU-Perth-FSH

    Perth, Australia

  • AU-Perth-RPH

    Perth, Australia

  • AU-Perth-SCGH

    Perth, Australia

  • AU-Sydney-CONCORD

    Sydney, Australia

  • AU-Sydney-NEPEAN

    Sydney, Australia

  • AU-Sydney-RNSH

    Sydney, Australia

  • AU-Sydney-WSAH

    Sydney, Australia

  • St George Hospital

    Sydney, Australia

  • AU-Waratah-CALVARYMATER

    Waratah, Australia

  • AT-Graz-MEDUNIGRAZ

    Graz, Austria

  • AT-Innsbruck-IMED

    Innsbruck, Austria

  • AT-Linz-KEPLER

    Linz, Austria

  • AT-Linz-ORDENSKLINIKUM

    Linz, Austria

  • AT-Salzburg-SALK

    Salzburg, Austria

  • AT-Vienna-HANUSCH

    Vienna, Austria

  • BE-Antwerpen-ZNASTUIVENBERG

    Antwerp, Belgium

  • BE-Brugge-AZBRUGGE

    Bruges, Belgium

  • BE-Brussel-BORDET

    Brussels, Belgium

  • BE-Bruxelles-STLUC

    Brussels, Belgium

  • BE-Gent-UZGENT

    Ghent, Belgium

  • BE-Haine-Saint-Paul-JOLIMONT

    Haine-Saint-Paul, Belgium

  • BE-Hasselt-VIRGAJESSE

    Hasselt, Belgium

  • BE-Leuven-UZLEUVEN

    Leuven, Belgium

  • BE-Liege-CHRCITADELLE

    Liège, Belgium

  • BE-Liege-CHULIEGE

    Liège, Belgium

Showing 40 of 193 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.